相关实验视频

Updated: Jun 13, 2025

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Published on: September 9, 2021

一种抗纤维素化合物,可以改善细胞和HFD小鼠模型中的高血糖和脂肪积累

Tsugumasa Toma¹, Nobukazu Miyakawa², Yuiichi Arakaki¹

¹Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

|September 9, 2024

概括

新型化合物HPH-15有效降低血糖,并改善糖尿病小鼠的胰岛素抵抗. 与甲福明相比,HPH-15还表现出优越的减脂和抗纤维作用,表明其作为糖尿病治疗的潜力.

科学领域:

生物化学生化学
药理学药理学是指药理学的学科.
代谢疾病代谢疾病

背景情况:

糖尿病管理需要控制血糖并预防并发症.
AMP激活蛋白激酶 (AMPK) 激活是糖尿病治疗的关键目标.
HPH-15是一种先前识别的化合物,具有抗纤维素和AMPK激活特性.

研究的目的:

评估HPH-15作为潜在的糖尿病治疗药物.
评估HPH-15对AMPK激活,葡萄糖吸收和脂肪积累的影响.
在临床前模型中比较HPH-15与甲福林的疗效.

主要方法:

使用L6-GLUT4,HepG2和3T3-L1细胞模型进行体外研究,以评估AMPK激活,葡萄糖吸收,脂肪积累和乳酸产生.
使用高脂肪饮食 (HFD) 的小鼠进行体内研究,以评估降糖,抑制脂肪,抗纤维和AMPK激活作用.
与同等或更高剂量的甲胺对HPH-15疗效的比较.

主要成果:

在细胞模型中,HPH-15显著增加了AMPK激活,葡萄糖吸收和GLUT4转位,与甲福明相比.
在HFD养的小鼠中,HPH-15降低了血糖水平,改善了胰岛素抵抗.
与甲福明相比,HPH-15表现出更好的抑制脂肪积累和肝纤维化,高剂量可将皮下脂肪减少44%.

结论:

HPH-15激活AMPK的度低于甲胺,在体外和体内.
HPH-15可以改善血糖控制和胰岛素抵抗,并比甲福明更有效地改善脂肪肝和纤维化.
HPH-15显示为糖尿病的多作用治疗药物,解决高血糖症,胰岛素耐药性以及脂肪肝和过度脂肪积累等相关并发症.

关键词:

由AMP激活的蛋白质激酶激活的蛋白质激酶.糖尿病糖尿病糖尿病脂肪肝是一种脂肪肝.在GLUT4中使用GLUT4.4型葡萄糖输送器 4型葡萄糖输送器肥胖问题肥胖问题皮下脂肪是一种皮下脂肪.

更多相关视频

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...